-
Swiatek races into Toronto semis as Svitolina battles through
-
Oil prices rise further as hopes for Hormuz deal fade
-
'Big Four' bowlers back as ageing Australia begin gruelling run
-
One year after Putin-Trump summit, 'spirit of Anchorage' dissipated
-
AI's hunger for power sparks US private gas plant boom
-
Farage vs Count Binface: What to know about UK snap poll
-
Memphis AI data center fuels pollution fight in Black neighborhood
-
Torment of Afghan fathers as daughters deprived of education
-
Ceuta leader wants migrant detention centre after influx
-
Return of displaced Syrian Kurds to hometown suspended after violence
-
Colombia scrambles to find survivors as quake kills 111
-
Swiatek races past Shnaider into Toronto semi-finals
-
Rain postponements wreck Montreal Masters schedule
-
Meta pushes global AI vision amid race with OpenAI, Anthropic and China
-
Notts Forest owner Marinakis sues Palace over gun banner - reports
-
US judge ends graft case against India's Adani
-
Koech gets three-year ban, stripped of US 1,500m title
-
Anderson retires after 10 MLB seasons after 'too much pain'
-
Sensational Ingebrigtsen back with more European gold
-
Colombia in state of emergency as quake kills 111
-
'A scare': Brazil player leaps into tunnel in joy over goal
-
Britain's Amy Hunt wins European women's 100m gold
-
USA Swimming CFO Hilliard arrested for alleged theft
-
Trump order pushes for overhaul of childhood vaccine schedule
-
Trump insists Netanyahu relationship 'very good' despite Gaza rift
-
Global stocks mixed while oil prices jump on Hormuz
-
Ingebrigtsen delivers masterclass for seventh European athletics gold
-
Turkey MPs back historic law on reintegrating Kurdish militants
-
Colombia declares state of emergency after quake kills 111
-
'Dreams disappear' as Gaza students await evacuation to Italy
-
Golden relay double for Britain at Europeans as Marchand takes silver
-
Third European gold for Schilder in women's shot put
-
Barcelona's Araujo heads to Liverpool on loan
-
Golden relay double for Britain at Europeans as Marchand settles for silver
-
Tupac Shakur murder trial begins 30 years after rapper's death
-
US had hottest month on record in July
-
Russia bars only anti-war party from elections
-
Colombia quake leaves 69 dead, with more trapped under rubble
-
Boeing to divest tech ventures for stake in air-taxi startup
-
Bookmap Announces Partnership with Plus500 to Expand Futures Trading Access
-
Major quake rocks Colombia and neighbors, 18 confirmed dead
-
Barcelona turn down PSG offer for Torres
-
Brazil aircraft maker Embraer raises outlook after record revenue
-
Buildings collapse as major quake rocks Colombia and neighbors
-
Drought forces water restrictions across nearly 70 percent of France
-
Meta releases new AI model as Zuckerberg lays out vision
-
Europe wary as gas stocks languish at lows while winter looms
-
Freedom Holding Corp. Reports 40% Increase in Quarterly Revenue to $732.5 Million
-
OFunded Enters the Prop Trading Market With Broker-Backed Infrastructure From OFinancial Markets
-
What next for beleaguered FIFA president Infantino?
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.Henrique--PC